Ionis Pharmaceuticals Newsroom

Flamingo Therapeutics Announces Poster Presentation on AML Phase 1 IIT Study at ASH 2024

PR NewswireDec 4 08:00 ET

Theratechnologies Announced It Has Entered Into An Agreement With Ionis Pharmaceuticals To License Two Investigational RNA-targeted Medicines Developed By Ionis

BenzingaDec 4 07:40 ET

Raymond James Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $61

Moomoo NewsDec 2 09:31 ET · Ratings

Express News | Ionis Pharmaceuticals Inc : Raymond James Adds Stock to Its Analyst Current Favorites List

ReutersDec 2 07:43 ET

J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $51

Moomoo NewsNov 28 07:31 ET · Ratings

Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and GoodRx Holdings (GDRX)

TipRanksNov 28 07:10 ET · Ratings

Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Nov 27 11:15 ET

Praxis Precision Medicines to Showcase Updates From Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting

GlobeNewswireNov 26 08:00 ET

Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby

Seeking AlphaNov 23 08:26 ET

Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now

Yahoo FinanceNov 19 19:08 ET

Here's Why Ionis Pharmaceuticals (IONS) Is Poised for a Turnaround After Losing -13.46% in 4 Weeks

Zacks Nov 18 08:50 ET

Express News | Shares of Pharmaceutical and Healthcare Stocks Are Trading Lower. The Sector Has Been Under Pressure After President-elect Trump Nominated Robert F. Kennedy Jr. to Lead the HHS

BenzingaNov 15 15:21 ET

Catalyst Watch: Nvidia Earnings, Microsoft Ignite, Crypto Confidence, and P&G Event

Seeking AlphaNov 15 15:00 ET

Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler

Dow JonesNov 14 09:26 ET · Ratings

Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer

PR NewswireNov 14 08:00 ET

Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $62

Moomoo NewsNov 14 07:31 ET · Ratings

10 Health Care Stocks Whale Activity In Today's Session

BenzingaNov 12 12:35 ET

Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Lagging The Industry But So Is The Business

Simply Wall StNov 9 07:07 ET

A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $45 to $77

Moomoo NewsNov 8 08:00 ET · Ratings

Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Yahoo FinanceNov 8 05:46 ET